NovelStem International Corp. is a development stage biotech and media investment company, mainly holding stakes in biotech research and media assets, with no current revenue or employees, and significant financial losses due to investments and impairments.

# Company Summary: NovelStem International Corp.

## Overview
- **Type of Company:** Holding company
- **Principal Assets:** 
  - 50% equity interest in **NetCo Partners** (a media publishing venture)
  - Approximately 31% ownership in **NewStem Ltd** (an Israeli biotech company)
- **Business Focus:** Transitioned from media to biotech; mainly invests in biotech assets and technology

## Business Operations
- **Current Main Activities:** 
  - Investing in and holding biotech assets, specifically in stem cell technology developed by Hebrew University under license
  - Managing investments in NetCo, which owns the *"Net Force"* entertainment franchise (books, TV, video games)
- **Technology & Development:** 
  - Focused on human Pluripotent Stem Cells (hPSCs), especially Haploid human Pluripotent Stem Cells (HhPSCs)
  - Uses these cells for genome-wide screenings to discover oncology drug targets and diagnostics 
  - Developing AI-based drug discovery platforms, focusing on synthetic lethal interaction and personalized diagnostics for chemotherapy resistance
- **Intellectual Property & Licensing:**
  - Holds exclusive worldwide license from Hebrew University and The New York Stem Cells Foundation, based on research by Prof. Nissim Benvenisty
  - License pertains to development, manufacture, and commercialization of therapeutic and diagnostic products
  - Pays royalties of up to 3% of net sales and up to 12% of sublicense consideration
  
## Financial & Operational Status
- **Employees:** No current employees; operations rely on consultants
- **Customers:** No mention of direct customer base (typical for investment/holding company and biotech licensing)
- **Revenue:** Minimal or none from biotech operations; primarily investment income
- **Income:** The company has reported net losses:
  - $3,233,042 for 2024
  - $4,187,301 for 2023
- **Key Assets & Interests:**
  - Majority owned (around 30.51%) in NewStem, which performed research in cancer genetics and developed diagnostic platforms
  - 50% stake in NetCo, which owns media rights for the *"Net Force"* franchise
  
## Recent Developments
- In 2024, NewStem ceased operations and entered liquidation; the technology reverted to licensor Yissum
- The Company stored its investment in NewStem at a $1.63 million impairment loss in 2024
- Attempted acquisition of remaining NewStem shares was not completed due to funding issues
- The Company is pursuing the sale of its interest in NetCo to its joint venture partner, with a potential sale price of $1,300,000 announced in February 2025

## Summary
- A development stage biotech and media investment company primarily holding stakes in biotech research and media assets
- No current revenue or employees
- Significant financial losses due to investments and impairment of biotech assets
- Focuses on licensing, intellectual property, and strategic investments in biotech and entertainment properties

NovelStem International Corp. is a biotechnology holding company focused on advancing stem-cell based technologies through its investment in NewStem Ltd.

# Summary of NovelStem International Corp.

## Company Profile
**Name:** NovelStem International Corp.  
**Founded:** January 1993 (originally as Big Entertainment, Inc.)  
**Headquarters:** 2255 Glades Road, Boca Raton, FL 33431  
**Executive Chairman:** Jan Loeb  
**Primary Focus:** Biotechnology and stem-cell based technologies through its affiliate, NewStem Ltd.  
**Equity Interests:**  
- **NewStem Ltd:** Approx. 31%  
- **NetCo Partners:** 50%  

## Business Overview
NovelStem is a development stage biotechnology holding company focused on leveraging stem cell-based technology, particularly through its significant ownership interest in NewStem Ltd., an Israeli biotech company specializing in human Pluripotent Stem Cells (hPSCs) and Haploid human Pluripotent Stem Cells (HhPSCs). The primary applications of this technology center around cancer research, regenerative medicine, and disease therapy.

### NewStem Ltd.
- **Founded:** Year unspecified, operates in the biotechnology sector.
- **Main Innovations:**
  - Developed a discovery bio-platform based on haploid hPSCs technology.
  - Engaged in the discovery and development of oncology drugs and personalized diagnostics.
- **Regulatory Milestones:** 
  - Filed FDA Pre-Submission for its in vitro diagnostic device (NSDD) and received a CE Mark from the European Medicines Agency (EMA) for European distribution.
- **Intellectual Property:** Holds exclusive licenses from Yissum Research Development Company and The New York Stem Cells Foundation.
- **Financial Performance:** 
  - Has incurred losses since inception.
  - Generated minimal revenues primarily from a licensing agreement.
  - No dividend payments received in fiscal years 2022 and 2023.
  
### NetCo Partners
- **Founded:** June 1995 in partnership with C.P. Group Inc.
- **Ownership:** 50% interest by NovelStem and C.P. Group.
- **Focus:** Owns rights to the "Net Force" intellectual property across various media.
- **Financial Contributions:** Received distributions totaling $6,875 in 2023 and $12,591 in 2022.

## Financial Summary
- **Revenue:** Minimal revenue; primarily from licensing agreements.
- **Distributions from Affiliates:** 
  - NetCo distributions: $6,875 (2023), $12,591 (2022).
- **Total Costs related to litigation funding:** $2,819,196 (related to arbitration proceedings regarding NetCo).

## Operational Details
- **Employees:** NovelStem currently has no full-time employees, relying solely on consultants for operational duties.
- **Key Customers:** Not specified; however, the technologies and diagnostics are likely targeted at oncologists and the healthcare industry for cancer treatment.

## Competitive Overview
- **Competition:** Faces competitive pressure in the biotechnology sector, particularly in stem cell research.
- **Market Landscape:** Rapid technological advancements necessitate continuous enhancement of its product offerings to meet customer demands.

## Conclusion
NovelStem International Corp. is highly focused on advancing innovative stem cell technologies primarily through its investment in NewStem Ltd., while maintaining a significant equity interest in its joint venture, NetCo Partners. The company remains in a development stage with ongoing research and regulatory milestones, while yet to achieve significant revenue generation. The reliance on its key executives and strategic developments is crucial for future growth and operational success.

NovelStem International Corp.

10-K / April 7, 2025

10-K / April 1, 2024

10-K / April 7, 2025

Company Summary: NovelStem International Corp.

Overview

Business Operations

Financial & Operational Status

Recent Developments

Summary